BofA raised the firm’s price target on Scholar Rock (SRRK) to $50 from $49 and keeps a Buy rating on the shares after the company provided updates around the apitegromab BLA resubmission, apitegromab’s second indication, and the next-generation myostatin inhibitor SRK-439 at the JPMorgan healthcare conference.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock: Apitegromab Manufacturing Resolution and Pipeline Expansion Underpin Buy-Rated Risk-Reward Profile
- Scholar Rock Details 2026 Strategy and Regulatory Priorities
- Scholar Rock initiated with a Buy at Citi
- Buy/High Risk: Apitegromab’s Differentiated SMA Profile and Expanding Neuromuscular Upside Support Significant Re-Rating Potential
- Scholar Rock initiated with a Buy at UBS